Status:
UNKNOWN
Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride Injection
Lead Sponsor:
Qianfoshan Hospital
Conditions:
Adverse Reaction
Cardiotoxicity
Eligibility:
All Genders
Brief Summary
To study the current status of cardiotoxicity of arsenious acid by analyzing the literature, monitoring data, and real-world applications, and to discuss risk factors and preventive and control measur...
Detailed Description
Through the project study, the risk rate of cardiotoxicity caused by arsenious acid will be verified and evaluated, and a typical case analysis will be conducted to assess the risk and benefit ratio o...
Eligibility Criteria
Inclusion
- the period of consultation (for inpatients, according to the time of admission) is from January 1, 2012 to December 31, 2022
- the patient used arsenite sodium chloride injection
Exclusion
- Patients with incomplete clinical information
Key Trial Info
Start Date :
January 29 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06060132
Start Date
January 29 2023
End Date
December 31 2023
Last Update
September 29 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
China
Jinan, Shandong, China, 250014
2
First Affiliated Hospital of Shandong First Medical University ( Qianfoshan Hospital of Shandong Province )
Jinan, Shandong, China, 250014